Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Yuhan Corporation
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06041529CT.gov Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension | — | Active Not Recruiting | — | — | — |
NCT05843162CT.gov A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome | — | Unknown | — | — | — |
NCT06282549CT.gov Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Essential Hypertension
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Telmisartan (this asset) | Yuhan Corporation | Approved | B · 63 |
| Hydrochlorothiazide | Yuhan Corporation | P4 | BBB |
| Amlodipine | Yuhan Corporation | P4 | BBB |
| Tomato Fruit Extract | Beata Krasinska | P4 | BB |
| Phentermine | VIVUS LLC | P4 | BB |
| Valsartan | ARKAY Therapeutics | P4 | BB |
| Labetalol | ProMedica Health System | P3 | BB |
| vi-0521 | VIVUS LLC | P4 | BB |
| Glibenclamide | University of Campinas, Brazil | P4 | BB |
+35 more in the Essential Hypertension cohort
Other indications for Telmisartan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hypertensive Disorder | — | P4 | BB · 71 |
| Abdominal Obesity-Metabolic Syndrome | — | P4 | BB · 70 |
| Schizoaffective Disorder | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Telmisartan in Essential Hypertension. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/telmisartan-essential-hypertension
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →